Capital Is Beginning to Match Capability.
India’s biotechnology ecosystem is entering a more consequential phase of development. With more than 10,000 biotech startups, a bioeconomy exceeding USD 165 billion, and rising policy focus on innovation and biomanufacturing, the sector today reflects real scale and long-term intent.
Yet scale alone does not equal maturity. Scientific capability and entrepreneurial ambition have advanced rapidly, while capital structures and exit mechanisms are still evolving. This balance between progress and persistence defines the current phase of Indian biotech.
Where Indian Biotech Stands Today
India now hosts one of the largest and most diverse biotech startup ecosystems globally. The momentum is visible not only in numbers, but in the kinds of problems companies are trying to solve. Startups are active across cell therapy, oncology platforms, regenerative medicine, antimicrobial resistance, and biomanufacturing technologies.
On the enabling side, India’s life sciences infrastructure has also improved. Access to CRDMOs, GMP manufacturing, and early clinical capabilities has expanded, allowing more companies to progress further along the value chain while remaining operationally anchored in India.
At a high level, the ecosystem now looks less like a collection of isolated startups and more like a connected pipeline that can support translation from lab to clinic.
How Capital Engagement Is Evolving
Historically, capital in Indian biotech gravitated toward lower-risk models such as diagnostics, services, and manufacturing-adjacent businesses. This reflected rational concerns around long timelines, regulatory uncertainty, and limited exit visibility.
That engagement is now becoming more structured. Investors are increasingly backing companies that demonstrate clear milestone planning, regulatory alignment, and capital efficiency. Public capital mechanisms, better infrastructure, and stronger policy direction have reduced early-stage friction and helped companies reach meaningful value-inflection points.
In other words, capital is not becoming reckless. It is becoming more informed.
CRDMO Exits: A Useful Signal, With Important Limits
One important development in recent years has been the emergence of successful exits in the CRDMO and research services space. For investors, CRDMOs are often easier to underwrite than discovery-led biotech because they tend to have clearer business models, earlier revenue visibility, and more predictable unit economics once scale is achieved.
CRDMO exits matter beyond the services category. They validate two broader points about Indian life sciences. First, global buyers and strategic acquirers value India-based scientific execution, manufacturing quality, and cost efficiency. Second, they demonstrate that exits are possible in Indian life sciences when risk is structured around delivery, compliance, and execution.
At the same time, it is important not to over-interpret this signal. CRDMO exits and discovery-led biotech exits are fundamentally different. CRDMOs scale through contracts, capacity, and regulatory compliance. Discovery-led biotech scales through clinical outcomes, regulatory milestones, and intellectual property creation. The timelines, capital requirements, and valuation logic are not the same.
CRDMO exits do not solve the exit challenge for drug discovery. But they do strengthen confidence that parts of India’s life sciences ecosystem already have functioning and repeatable exit pathways.
Where the Constraints Still Exist
Despite progress, several foundational issues remain.
Exit pathways for discovery-led biotech remain the most significant constraint. Large venture-style exits based on drug pipelines are still rare. Without repeatable benchmarks, investor confidence builds gradually.
Biotech also remains a long-gestation, high-risk asset class. Drug discovery and advanced biologics require years of experimentation, clinical validation, and regulatory approval. These timelines are inherent.
The pool of specialist investors remains limited, resulting in slower deal cycles and conservative valuations. Domestic valuation frameworks still lag global norms, with cash flow visibility often taking precedence over probability-weighted IP valuation.
Healthcare reimbursement and pricing visibility also remain limited, complicating long-term revenue modelling and reinforcing cautious capital deployment.
Why the Opportunity Still Holds
Acknowledging these realities strengthens, rather than weakens, the investment case.
Indian biotech no longer faces uncertainty around scientific capability. The open questions today are about timing, capital depth, and exit normalization. For long-term investors, this creates a window where risk is better understood, valuations remain disciplined, and asset quality continues to improve.
This is also why the opportunity is not one-size-fits-all. Some investors will prefer CRDMO and enabling platforms with earlier revenue. Others will pursue discovery-led bets with longer horizons. Both can be valid, and both benefit from the same underlying ecosystem expansion.
Looking Ahead
Indian biotech has moved beyond questions of potential. The ecosystem now operates with real scientific depth, improving execution capability, and increasing global relevance.
The next inflection point will come as capital confidence and exit pathways begin to align more consistently with the quality of science and services being built. That alignment is already starting. When it accelerates, value creation will follow across the life sciences stack, from services and manufacturing to platforms and therapeutics.
Written by: Anirudh Srinivasan | CGO & Co-Founder
Anirudh leads growth and commercial strategy at GVRP, working closely on partnerships, market expansion, and how the platform evolves over time.